| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.04. | Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates | 121 | GlobeNewswire (Europe) | ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02... ► Artikel lesen | |
| 29.03. | Eloxx Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.03. | NSE - Eloxx Pharmaceuticals, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| 20.03. | Delisting of Securities of Latch, Inc.; Eloxx Pharmaceuticals, Inc.; Collective Audience, Inc. (f.k.a., ABRIC SPAC I); SeqLL Inc.; Nemaura Medical Inc.; LumiraDx Limited; Cemtrex Inc.; COMSovereign Holding Corp.; Global System Dynamics; Arrival ... | 196 | GlobeNewswire (Europe) | NEW YORK" March 20, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock and warrants of Latch, Inc. Latch, Inc.'s securities were suspended on August... ► Artikel lesen | |
| 14.03. | Eloxx Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.03. | Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases | 273 | GlobeNewswire (Europe) | Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready... ► Artikel lesen | |
| 13.03. | Almirall, S.A.: Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases | 340 | Business Wire | Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a... ► Artikel lesen | |
| 13.03. | Almirall and Eloxx Pharmaceuticals Enter Exclusive License agreement for ZKN-013 | 2 | Contract Pharma | ||
| 13.03. | ALMIRALL, S.A.: License agreement with Eloxx Pharmaceuticals | 5 | CNMV | ||
| 24.01. | Eloxx Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 09.01. | Eloxx Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 28.12.23 | Eloxx Pharmaceuticals, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 15.12.23 | Eloxx Pharmaceuticals, Inc. - 8-K, Current Report | 6 | SEC Filings |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TUI | 3.803 |
| NVIDIA | 2.632 |
| GAMESTOP | 2.134 |
| NEL | 1.908 |
| BAYER | 1.740 |
| EVOTEC | 1.618 |
| PLUG POWER | 1.606 |
| BYD | 1.127 |
| VOLKSWAGEN | 762 |
| SUPER MICRO COMPUTER | 761 |
| DEUTSCHE LUFTHANSA | 680 |
| RHEINMETALL | 676 |
| BIONTECH | 617 |
| AIXTRON SE | 594 |
| ALLIANZ | 498 |
| BASF | 491 |
| DEUTSCHE TELEKOM | 491 |
| OMV | 483 |
| PALANTIR TECHNOLOGIES | 478 |
| THYSSENKRUPP | 478 |
| NOVAVAX | 475 |
| TESLA | 474 |
| DEUTSCHE BANK | 461 |
| SIEMENS ENERGY | 458 |
| RWE | 446 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
